These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22160076)

  • 41. An approach to prevent the severe adverse events associated with transfusion of FDA-approved blood products.
    Valeri CR; Ragno G
    Transfus Apher Sci; 2010 Jun; 42(3):223-33. PubMed ID: 20392670
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Removal of biologic response modifiers associated with platelet transfusion reactions: strategies worth considering?
    Garraud O; Cognasse F; Hamzeh-Cognasse H; Spinelli S; Phipps RP; Blumberg N
    Transfusion; 2014 Oct; 54(10):2583. PubMed ID: 25302737
    [No Abstract]   [Full Text] [Related]  

  • 43. Release of biologically active CD154 during collection and storage of platelet concentrates prepared for transfusion.
    Kaufman J; Spinelli SL; Schultz E; Blumberg N; Phipps RP
    J Thromb Haemost; 2007 Apr; 5(4):788-96. PubMed ID: 17403203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Glycans and glycosylation of platelets: current concepts and implications for transfusion.
    Sørensen AL; Hoffmeister KM; Wandall HH
    Curr Opin Hematol; 2008 Nov; 15(6):606-11. PubMed ID: 18832932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of the duration of platelet storage in critically ill trauma patients.
    Inaba K; Branco BC; Rhee P; Blackbourne LH; Holcomb JB; Spinella PC; Shulman I; Nelson J; Demetriades D
    J Trauma; 2011 Dec; 71(6):1766-73; discussion 1773-4. PubMed ID: 22182887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improving platelet transfusion safety: biomedical and technical considerations.
    Garraud O; Cognasse F; Tissot JD; Chavarin P; Laperche S; Morel P; Lefrère JJ; Pozzetto B; Lozano M; Blumberg N; Osselaer JC
    Blood Transfus; 2016 Mar; 14(2):109-22. PubMed ID: 26674828
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of predictors of severity for recipient adverse reactions during platelet product transfusions.
    Sut C; Tariket S; Cognasse F; Garraud O
    Transfus Clin Biol; 2017 Jun; 24(2):87-91. PubMed ID: 28479028
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets.
    Jacobs MR; Good CE; Lazarus HM; Yomtovian RA
    Clin Infect Dis; 2008 Apr; 46(8):1214-20. PubMed ID: 18444858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. ABO incompatible platelets: risks versus benefit.
    Dunbar NM; Ornstein DL; Dumont LJ
    Curr Opin Hematol; 2012 Nov; 19(6):475-9. PubMed ID: 22914587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions.
    Hamzeh-Cognasse H; Damien P; Nguyen KA; Arthaud CA; Eyraud MA; Chavarin P; Absi L; Osselaer JC; Pozzetto B; Cognasse F; Garraud O
    Transfusion; 2014 Mar; 54(3):613-25. PubMed ID: 23944651
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A computerized prediction model of hazardous inflammatory platelet transfusion outcomes.
    Nguyen KA; Hamzeh-Cognasse H; Sebban M; Fromont E; Chavarin P; Absi L; Pozzetto B; Cognasse F; Garraud O
    PLoS One; 2014; 9(5):e97082. PubMed ID: 24830754
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The platelet storage lesion.
    Devine DV; Serrano K
    Clin Lab Med; 2010 Jun; 30(2):475-87. PubMed ID: 20513565
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Platelet transfusions.
    Kelton JG; Blajchman MA
    Can Med Assoc J; 1979 Nov; 121(10):1353-8. PubMed ID: 391376
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [In vitro platelet production].
    Dunois-Lardé C; Baruch D
    Transfus Clin Biol; 2011 Apr; 18(2):158-64. PubMed ID: 21411355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Generation of inflammatory cytokines and chemokines from peripheral blood mononuclear cells by HLA Class II antibody-containing plasma unit that was associated with severe nonhemolytic transfusion reactions.
    Sakagawa H; Miyazaki T; Fujihara M; Sato S; Yamaguchi M; Fukai K; Morioka M; Kato T; Azuma H; Ikeda H
    Transfusion; 2007 Jan; 47(1):154-61. PubMed ID: 17207244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The acellular fraction of stored platelets promotes tumor cell invasion.
    Dineen SP; Roland CL; Toombs JE; Kelher M; Silliman CC; Brekken RA; Barnett CC
    J Surg Res; 2009 May; 153(1):132-7. PubMed ID: 18541268
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activation of platelet concentrate during preparation and storage.
    Rinder HM; Snyder EL
    Blood Cells; 1992; 18(3):445-56; discussion 457-60. PubMed ID: 1283703
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol).
    Azuma H; Hirayama J; Akino M; Miura R; Kiyama Y; Imai K; Kasai M; Koizumi K; Kakinoki Y; Makiguchi Y; Kubo K; Atsuta Y; Fujihara M; Homma C; Yamamoto S; Kato T; Ikeda H
    Transfusion; 2009 Feb; 49(2):214-8. PubMed ID: 18798806
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Transfusion of platelet concentrates].
    Rieux C; Lee K; Lavaud A; Bierling P
    Ann Med Interne (Paris); 1999 Dec; 150(8):631-41. PubMed ID: 10686645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.